Dual Therapeutics is an oncology company developing novel therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Founded in 2013, the company’s technology is based on research developed and exclusively licensed from the Mount Sinai School of Medicine and Case Western Reserve University. Currently, Dual Therapeutics is at the development compound nomination milestone.
Dual Therapeutics’ lead candidate is a first-in-class, orally bioavailable, direct small-molecule activator of a tumor suppressor PP2A, a serine / threonine phosphatase. In contrast to kinase-directed drugs, which block individual oncogenic signaling pathways through inhibition of positive regulatory signals, this approach simultaneously blocks multiple oncogenic pathways through activation of the key negative regulator PP2A. This novel approach allows a more comprehensive assault on cancer cells while sparing normal cells in which PP2A function is not disregulated. It is anticipated that this therapy may hold benefit for patients suffering from a wide range of malignancies.
This technology not only addresses a high unmet medical need, but that also presents a significant commercial opportunity. Current gold standard treatments for prostate cancer (Zytiga and Xtandi) have had peak annual sales of close to $2 billion, yet their efficacy is limited to extending overall survival by about five months. At the same time, over four million people worldwide have been diagnosed with T-cell acute lymphoblastic leukemia, but there is no treatment available for patients who relapse. The Dual Therapeutics compound has shown superior results in numerous in vivo models, suggesting that it may meaningfully advance the standard of care for these diseases.